||The Centers for Disease Control reported that from 2015 to 2016 the prevalence of obesity was at nearly 40% of the United States' population, equating to roughly 93 million people (Hales, Carroll, Fryar, & Ogden, 2017). The significance of these values presents a large and costly burden to the healthcare system through pharmaceutical requirements (Paoli, Rubini, Volek, & Grimaldi, 2013). The propensity for obese individuals to develop metabolic syndrome (hypertension [HTN], type 2 diabetes [T2DM], obesity, and hyperlipidemia [HLD]) is outstanding (Abbasi, 2018; Mayo Clinic, 2018). Many different approaches have been made to lower the obesity rates in America through medication and lifestyle management; however, this has proven to be very difficult for providers and patients to maintain due to weight regain after the diet is stopped (Nymo et al., 2017). Some evidence supports ketogenic diet (KD) as a superior weight-loss therapy for obese persons, with self-reported increased satiety and metabolism in comparison to other diets (Abbasi, 2018).